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ABSTRACT
The optimal management of bacteraemia related to the presence of totally implantable venous access
devices (TIVADs) remains controversial, particularly in terms of whether to remove the infected
catheter. The objective of this study was to determine the factors associated with success or failure of
treatment of TIVAD-related bacteraemia in patients from whom the infected device was not removed.
The outcome of 92 episodes of TIVAD-related bacteraemia and the factors predictive of an unfavourable
outcome were evaluated retrospectively. In 32 (35%) episodes, the devices were removed immediately.
In 60 episodes, patients were treated with antibiotics infused through the device; treatment was
successful in 56% of these cases (66% for infections caused by coagulase-negative staphylococci). Only
the presence of sepsis (OR 9.42, 95% CI 1.29–68.92, p 0.0271) and of local signs of infection (OR 9.61,
95% CI 1.98–46.49, p 0.0049) independently predicted the failure of catheter-retaining treatment.
Finally, only one-third of the devices were retained. In conclusion, the large number of TIVADs that
are removed because of infection justiﬁes reconsidering the criteria for device removal. During catheter-
retaining treatment, the presence of local signs of infection or reported sepsis were independent factors
for reduced probability of retaining the device.
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INTRODUCTION
Achieving vascular access for patients requiring
long-term drug administration was a serious
and challenging problem until the development
of totally implantable venous access devices
(TIVADs) in the early 1980s. TIVADs have
provided a reliable and convenient means of
administering therapeutic agents or parenteral
nutrition to patients suffering from severe or
chronic conditions, e.g., cancer, or who are hos-
pitalised following organ transplantation. The use
of these devices has facilitated the treatment of
many medical disorders and has improved
patients’ quality of life by affording unrestricted
mobility. However, infection is one of the most
common complications of TIVAD use, and cath-
eter-related sepsis is the most frequent life-threat-
ening complication of vascular catheters [1].
Infection rates reported for TIVADs range from
0.2 to 2.5 episodes ⁄ 1000 device-days [2–6], and
infection is implicated in as many as 50% of cases
involving device removal [6]. However, the opti-
mal management of TIVAD-related bacteraemia
remains controversial. The objectives of the pre-
sent study were to determine the outcome of
TIVAD-related bacteraemia in patients treated
without removal of the infected device, and to




The study was performed at Erasme Hospital (Universite´ Libre
de Bruxelles, Brussels, Belgium), an 858-bed academic hospital
that admits c. 27 000 patients annually. All patients who
developed TIVAD-related bacteraemia between 1996 and
2000 were included in the study. Patients were identiﬁed from
the database of the Infection Control Unit’s prospective
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surveillance programme for nosocomial bacteraemia. The
following clinical data were collected: associated co-morbidi-
ties; site of TIVAD insertion (jugular vein, femoral vein or
basilar vein); indication for use of device; date of bacteraemia;
delay from TIVAD insertion to development of bacteraemia;
presence of local signs of infection or sepsis, as reported in the
medical chart; microbiological data; leukocyte count; antimi-
crobial treatment; reasons for eventual TIVAD removal; and
outcome. If any variable was not available in the patient’s
chart, the patient was excluded from the analysis related to
that variable; therefore, the denominator for each analysis
varied according to the data available.
Implanted devices
During the 5-year study, 1016 TIVADs were inserted in Erasme
Hospital. The catheters used were the centrally placed subcu-
taneous Infusaport, Port-a-Cath (Sims Deltec, St Paul, MN,
USA), inserted into the internal jugular vein or the femoral
vein, and the peripherally placed port system, PAS port
(Pharmacia Deltec, St Paul, MN, USA), inserted into the basilar
vein.
Deﬁnitions
According to deﬁnitions published previously, deﬁnite
TIVAD-related bacteraemia was deﬁned as at least one
positive peripheral blood culture plus either local infection
with isolation of the same organism in the exudates at the
insertion site and in the bloodstream, or a positive quantitative
blood culture obtained from the TIVAD of ‡100 CFU ⁄mL for
the same organism as in the peripheral blood, or differential
quantitative blood cultures with a ‡ﬁve-fold increased colony
count of organisms isolated from blood drawn from the
TIVAD and simultaneously from peripheral venous blood
cultures. Probable TIVAD-related bacteraemia was recorded
following isolation of coagulase-negative staphylococci (CNS)
and other common skin organisms when no blood was
available from the TIVAD and when at least two positive
blood cultures drawn from different peripheral sites were
positive for the same organism (harbouring the same anti-
biotype), with no other identiﬁed source of infection [1,7].
Early and late infections were deﬁned as infections occurring
within or beyond the ﬁrst 30 days of TIVAD insertion,
respectively.
Local signs of infection were separated into pocket infec-
tion, tunnel infection or unspeciﬁed infection. Pocket infection
was deﬁned as induration, erythaema and tenderness of the
skin over the site of the TIVAD placement, or purulent
exudates in the subcutaneous pocket containing the device.
Tunnel infection was deﬁned as erythaema, tenderness and
induration in the tissues overlying the catheter that were
>2 cm from the portal edge [7].
Reported sepsis was recorded if the attending physician
noted the presence of sepsis in the medical chart.
Non-catheter-retaining treatment was deﬁned as a decision
to remove the TIVAD with no attempt to retain it. Catheter-
retaining treatment was deﬁned as an attempt to treat the
patient with the infected device in situ. Catheter-retaining
treatment was deﬁned as optimal when antimicrobial drugs
were administered through the device for ‡10 days (or until
clinical failure led to the removal of the TIVAD) at adequate
doses and frequency, and adapted to the microorganism’s
susceptibility proﬁle; any other conditions were deﬁned as
non-optimal catheter-retaining treatment. Clinical and micro-
biological responses were evaluated only in patients who
received catheter-retaining treatment.
Success was deﬁned as a clinical response within 48 h, with
no further positive blood cultures for the same microorganism
in the 4-week period following the end of the antibiotic course
without removal of the catheter.
Failure was deﬁned as no clinical response, or persistent
bacteraemia after 48 h of optimal treatment, or death attribut-
able to the infection, or removal of the TIVAD during the
antimicrobial treatment period.
Relapse was deﬁned as positive blood cultures with the
same microorganism and susceptibility proﬁle within the
4-week period following the end of antimicrobial treatment.
The outcome was considered to be non-evaluable if death
unrelated to infection occurred before the end of antimicrobial
treatment.
Death was attributed to infection when it occurred within
7 days of the last positive blood culture and no other
immediate cause of death was found.
Statistical analyses
Statistical analysis was performed using EpiInfo software
(CDC, Atlanta, GA, USA). The difference in proportions was
tested with the chi-square test or Fisher’s exact test, as
appropriate, with p <0.05 considered to be signiﬁcant. The
potential inﬂuence of a number of co-variates on the efﬁcacy of




Sixty-seven patients (38 males) presented with a
total of 92 (78 deﬁnite and 14 probable) episodes
of TIVAD-related bacteraemia. The median age
was 52 (range 20–87) years. Fifty-six patients had
one episode of bacteraemia, seven had two
episodes, two had three episodes, one had six
episodes, and one had ten episodes of TIVAD-
related bacteraemia. Major underlying co-morbi-
dities are summarised in Table 1. Indications for
insertion of a TIVAD (some patients had more
than one indication) included chemotherapy
(n = 55), parenteral nutrition (n = 36) and other
reasons (n = 14). Eighty-four (91%) of 92 episodes
involved a Port-a-Cath, with eight (9%) episodes
involving a PAS port.
Clinical presentation
Nineteen (21%) of 92 episodes occurred in the ﬁrst
30 days after insertion. Bacteraemia in 27 (29%) of
92 episodes was associated with local signs of
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infection, i.e., pocket infection (n = 22), tunnel
infection (n = 1) and unspeciﬁed local signs
(n = 4) (Table 2). Twelve (63%) of 19 early infec-
tions were associated with local signs of infec-
tion, compared with 15 (21%) of 73 late infections
(RR 3.07, 95% CI 1.74–5.42, p <0.001).
In 23 (25%) of 92 episodes, patients were
reported on the medical chart as having sepsis
when infection occurred. Twenty-seven patients
were neutropenic (£1000 polymorphonuclear
cells ⁄mm3). In the 59 non-neutropenic patients
with initial leukocyte determination, the median
leukocyte count was 9000 ⁄mm3 (range 1900–
32 400 ⁄mm3; normal value 4500–10 500 ⁄mm3),
the median polymorphonuclear count was
6984 ⁄mm3 (range 1216–31 104 ⁄mm3; normal value
1800–7700 ⁄mm3), and the C-reactive protein level
was 5.0 mg ⁄dL (range 0.5–30 mg ⁄dL; normal
value <1 mg ⁄dL).
In 32 (35%) of 92 episodes, the catheter was
removed immediately; these cases included two
patients presenting with septic shock, and patients
with one or more of the following reported
reasons: nature of the causative organism (fungi
n = 5, Pseudomonas aeruginosa n = 1, methicillin-
resistant Staphylococcus aureus n = 1, methicillin-
susceptible S. aureus n = 8), reported sepsis
(n = 12); local signs of infection (n = 10); relapse
following previous catheter-retaining treatment
(n = 8); and associated thrombosis or dysfunction
of the device (n = 2). Sixteen (50%) of 32 patients
hadmore than one of these conditions. No obvious
cause for removal was identiﬁed in three cases.
Culture of the devices immediately following
removal was performed in 28 episodes, and all
17 (61%) of the positive cultures were positive for
the same microorganism that was present in the
blood culture.
Of the 60 episodes that were treated without
device removal, three were not evaluated because
death occurred before the end of treatment and
was not attributed to bacteraemia (one case each
of massive haemoptysis, acute myocardial infarc-
tion and Fournier’s gangrene unrelated to the
TIVAD infection). The other 57 patients were
evaluable for catheter-retaining treatment.
Microbiological data
The 57 episodes of bacteraemia that were
evaluable for catheter-retaining treatment
yielded 70 microorganisms (Table 3). Forty-
seven episodes were monomicrobial. Of the
ten polymicrobial episodes, seven were caused
Table 1. Major underlying co-morbidities (not exclusive)














TIVAD, totally implantable venous access device.
Table 2. Nature of local signs of
infection and outcome of treatment
Nature of signs




Outcome of episodes with catheter-retaining treatment









Pocket infection 8 14 6 7 1
Tunnel infection 1 0 0 0 0
Unspeciﬁed 1 3 0 3 0
Total episodes with
local signs
10 17 6 10 1
Table 3. Distribution of causative microorganisms in
patients with catheter-retaining treatment




Methicillin-susceptible S. aureus 4
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by more than one skin ﬂora microorganism,
while three involved a mixture of CNS and
other non-skin ﬂora species.
Outcome of catheter-retaining treatment
The 57 episodes treated with an initial attempt to
retain the catheter all fulﬁlled the criteria for
optimal treatment. The median duration of treat-
ment (until the day of removal of the TIVAD if
performed following clinical or microbiological
failure of the retaining treatment) was 14 (range
2–44) days. Systemic antimicrobial therapies were
administered conventionally, with the exception
of continuous administration of vancomycin to
four patients. Six episodes were treated with
combination treatment (vancomycin plus rifampi-
cin for one methicillin-resistant S. aureus and ﬁve
CNS infections).
Thirty-two (56%) of 57 eligible episodes were
treated successfully with antibiotics (Table 4).
Relapses were observed in nine (16%) cases,
while catheter-retaining treatment failed in 16
(28%) cases. One (1.8%) death was attributed to
TIVAD-related bacteraemia in a neutropenic
leukaemia patient, with Lactobacillus salivarius
TIVAD-related bacteraemia and pneumonia,
who developed septic shock and died on the
second day of antimicrobial treatment. Fifteen
devices were removed following failure of con-
servative treatment after a median delay of 8
(range 2–20) days because of persistence of fever
in these 15 patients, ﬁve of whom had persistent
bacteraemia.
Eleven of the 13 removed devices that were
cultured were positive, all for the causative organ-
ism identiﬁed previously. Of 29 monomicrobial
CNS infections, catheter-retaining treatment was
successful in 19 (66%) episodes, unsuccessful in
ﬁve (17%) episodes, and was associated with
relapse in ﬁve (17%) episodes. Two of four
infections caused by methicillin-susceptible
S. aureus were cured, but none of three episodes
caused by methicillin-resistant S. aureus with
local signs of infection were cured. Catheter-
retaining treatment was successful in one of
four episodes involving Gram-negative bacilli.
Catheter-retaining treatment of seven episodes
with local signs of infection caused by CNS was
successful in four episodes (57%) and unsuccess-
ful in three (43%). Among CNS infections without
local signs (n = 22), catheter-retaining treatment
was successful in 15 (68%) episodes, failed in two
(9%) episodes, and was associated with relapse in
ﬁve (23%) episodes. A continuous infusion of
vancomycin was used successfully in four epi-
sodes. A combination of vancomycin plus rif-
ampicin was associated with a higher rate of
success (non-signiﬁcant) when compared to treat-
ment with vancomycin alone (four successes out
of ﬁve with combination therapy vs. 15 out of 24
with vancomycin-only treatment).
Determination of factors predictive of
unsuccessful catheter-retaining treatment
By univariate analysis, the causative organism
and the presence of local signs of infection were
associated with an increased risk of failure of
catheter-retaining treatment, with a trend towards
a higher risk of failure in patients with reported
sepsis (Table 5). Multivariate stepwise logistic
regression analysis showed that, of these three
co-variates, only the presence of reported sepsis
(OR 9.42, 95% CI 1.29–68.92, p 0.0271) and the
presence of local signs of infection (OR 9.61,
95% CI 1.98–46.49, p 0.0049) affected the outcome
of catheter-retaining treatment independently.
DISCUSSION
Treatment of infected TIVADs remains a chal-
lenge for the clinician, as vascular access must be
preserved for patients requiring long-term intra-
venous medication, while the risks of potential
systemic complications must also be considered.
There is general consensus that a catheter should
be left in situ during uncomplicated infection by
CNS without persisting or relapsing bacteraemia
[7]. However, it has been shown that, even in this
situation, catheter retention is associated with a
risk of recurrence of bacteraemia within 12 weeks
following standard parenteral therapy; thus, 20%
Table 4. Outcome of catheter-retaining treatment accord-








Coagulase-negative staphylococci (n = 29) 19 (66) 5 5
Methicillin-susceptible Staphylococcus aureus (n = 4) 2 (50) 1 1
Methicillin-resistant S. aureus (n = 3) 0 (0) 3 0
Gram-negative bacilli (n = 4) 1 (25) 3 0
Others and polymicrobial infections (n = 17) 10 (59) 4 3
Total (n = 57) 32 (56%) 16 (28%) 9 (16%)
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of patients whose catheters were not removed had
recurrent bacteraemia, compared with only 3% of
patients whose catheters were removed [8]. More-
over, in some populations, e.g., patients infected
with human immunodeﬁciency virus, even CNS
infections are associated with a poorer prognosis
[9]. In other cases, e.g., infection involving S. au-
reus [10–12], candidaemia [13,14], infection with
non-fermentative Gram-negative bacilli [15] or the
presence of local signs of infection (tunnel infec-
tion or port abscess) [5,16], optimal treatment is
not well-deﬁned and remains a subject of contro-
versy. These conditions, which are associated
with poor treatment success, are generally con-
sidered in most guidelines and reviews to be an
indication for removal of the device [7,17]. How-
ever, there are now some encouraging reports on
the ability of antibiotic therapy to cure infections
associated with intravascular devices without
device removal, even in high-risk conditions,
e.g., S. aureus or enterococcal infections
[3,4,18,19].
In the present study, c. one-third of episodes
resulted in immediate removal of the catheter, as
requested by the attending physician. Although,
in most cases, one or more factors associated with
a higher risk of failure were present, in some cases
it might have been preferable to ﬁrst try a device-
retaining treatment in order to prevent loss of the
valuable TIVAD and venous access. This under-
lines the importance of identifying with greater
accuracy the patients in whom the TIVAD could
be retained. The retrospective and observational
design of the present study allowed only limited
conclusions concerning the clinical management
of device-related bloodstream infection associated
with totally implantable devices. The lack of a
uniform treatment protocol for patients with port-
related bacteraemia, and the use of a clinical
deﬁnition of sepsis, made a comparison of epi-
sodes difﬁcult. The absence of molecular typing of
CNS probably resulted in an overestimate of the
number of episodes of probable TIVAD-related
bacteraemia. Nevertheless, even acknowledging
the limitations of the study, some practical treat-
ment recommendations can be formulated.
Treatment with catheter retention was success-
ful in 56% of cases, representing c. 30% of the total
cohort, which is a success rate similar to that
reported previously [7]. An absence of local signs
of infection was associated with a higher cure rate.
Similarly, infection caused by CNS had a better
prognosis, with a cure rate of 66%. The present
study suggests that the following factors did not
inﬂuence the risk of failure of catheter-retaining
treatment: chemotherapy-induced neutropenia;
delay between insertion and infection; site of
insertion (femoral or jugular in the case of Port-
a-Cath-associated infection); and clinical indica-
tion (parenteral nutrition vs. chemotherapy). Only
Table 5. Predictive factors for fail-




episodes Success Relapse Failure RRa 95% CI p
Site of insertion
Femoral 11 5 3 3 0.92 0.31–2.71 NS
Jugular 37 22 4 11
Indication
Parenteral nutrition 24 12 7 5 0.65 0.25–1.71 NS
Chemotherapy 25 15 2 8
Delay
£1 month 9 5 0 4 1.78 0.74–4.28 NS
>1 month 48 27 9 12
Number of polymorphonuclear cells
£1000 ⁄mm3 17 8 3 6 1.41 0.61–3.26 NS
>1000 ⁄mm3 40 24 6 10
Nature of episode
Polymicrobial 10 5 3 2 0.67 0.18–2.50 NS
Monomicrobial 47 27 6 14
Reported initial sepsis
Yes 9 3 1 5 2.42 1.11–5.30 0.099b
No 48 29 8 11
Local signs
Presence 17 6 1 10 4.59 1.85–11.40 0.0007b
Absence 39 26 8 5
Nature of microorganism
(46 monomicrobial episodes)
Other microorganisms 18 7 1 9 3.07 1.23–7.66 0.027
CNS 29 19 5 5
NS, not signiﬁcant; CNS, coagulase-negative staphylococci.
aRelative risk of failure (RR) was deﬁned as the risk when the corresponding factor was present compared with the
alternative.
bFischer’s test.
596 Clinical Microbiology and Infection, Volume 13 Number 6, June 2007
 2007 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 592–598
one death was attributed to TIVAD infection,
which was caused by septic shock associated with
neutropenia and at least one other concomitant
infection. This low rate of mortality is consistent
with data published previously [7].
In the present study, decisions for removal
without an attempt to retain the catheter ap-
peared to be largely consistent with published
recommendations. However, an attempt to retain
the catheter was made in some cases, despite the
presence of a causative microorganism for which
removal is usually recommended strongly. In
these situations, catheter-retaining treatment of
infections caused by S. aureus or Gram-negative
bacilli was associated with a higher rate of failure.
In contrast, a high rate of treatment success was
observed in patients with CNS infection, even
when accompanied by local signs of infection.
The present analysis found that catheter-retain-
ing treatment resulted in removal of the device for
about two-thirds of patients. This should prompt
an investigation of the beneﬁts of improved
identiﬁcation of patients for whom catheter-
retaining treatment should be proposed, or whe-
ther adjunctive therapies such as antibiotic lock,
antimicrobial combinations or continuous infu-
sions of antimicrobial drugs should be used.
Indeed, recent studies have indicated that the
efﬁcacy of vancomycin and other antimicrobial
agents has decreased markedly and that much
higher concentrations are needed to achieve
bioﬁlm eradication [20–23]. The present study
suggests that the presence of local signs and
sepsis are the only independent predictors of
treatment failure in patients with catheter-retain-
ing treatment. Despite some limitations caused by
the retrospective nature of the study, this ﬁnding
suggests that more restrictive indications for
initial removal of TIVAD should be considered,
at least for cases of CNS infection. Similarly,
optimal management of relapse caused by CNS
warrants further evaluation, and may not be an
absolute reason for TIVAD removal, particularly
when vascular access is difﬁcult, as most of these
cases have a relatively benign clinical course [24].
In conclusion, in two-thirds of cases of TIVAD-
related bacteraemia, the intravascular catheter
was lost, either with no attempt to retain it, or
because the catheter-retaining treatment failed.
Local signs of infection and reported sepsis were
independent predictive factors for failure in
patients with catheter-retaining treatment. The
successes observed in some high-risk cases, the
need to increase the rate of catheter salvage, and
the encouraging results of antibiotic lock or
combination therapy, should prompt clinicians
to reconsider current recommendations for imme-
diate removal and to better deﬁne the most
appropriate regimens for antimicrobial adminis-
tration.
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